Thus, the low cross-reactivity observed for the C9 clone, with satisfactory specificity (80%), suggest its use as a promising antigen in the serodiagnosis of strongyloidiasis, which may also include the C10 clone (77.5%). Here, C9 is linked to strongyloidiasis.